Fibrolamellar Carcinoma — Trials

Fibrolamellar Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

21 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 11
Recruiting: 8
Ph III recruiting: 0
Growth YoY: —
Industry share: 18%
Top sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (4)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06620302	Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma	suspended	Phase 1 / Phase 2	81	Children's Oncology GroupNETWORK	1	Aug 24, 2026	clinicaltrials
NCT05603572	KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)	suspended	Phase 1 / Phase 2	148	Primocure PharmaINDUSTRY	1	Jun 5, 2025	clinicaltrials